| Name | Title | Contact Details |
|---|---|---|
Ling Zeng |
Chief Legal and Administrative Officer | Profile |
Jeffrey Kopacz |
Vice President, Intellectual Property | Profile |
Ossium is building the world`s first bone marrow bank to treat blood cancers, improve organ transplantation, and repair damage from radiation.
Vitae Pharmaceuticals, Inc. focuses on discovering and developing drugs for various diseases. Its product candidates include VTP-34072, which is in a Phase II clinical trial for the treatment of type 2 diabetes; and VTP-37948 that is in Phase I clinical trials for alzheimer's disease. The company’s products in preclinical studies comprise VTP-43742 for the treatment of autoimmune disorders, such as psoriasis, multiple sclerosis, rheumatoid arthritis, Behcet's disease, and autoimmune uveitis; VTP-38443 for the treatment of acute coronary syndrome that consists of unstable angina and heart attacks; and VTP-38543 for the treatment of atopic dermatitis, an immune system mediated inflammation of the skin. Vitae Pharmaceuticals, Inc. has collaborations with Boehringer Ingelheim GmbH for the development of VTP-34072 and VTP-37948. Vitae Pharmaceuticals, Inc. was formerly known as Concurrent Pharmaceuticals, Inc. and changed its name to Vitae Pharmaceuticals, Inc. in January, 2005. The company was founded in 2001 and is headquartered in Fort Washington, Pennsylvania.
The Clemson University Biomedical Engineering Innovation Campus develops high-impact medical technology and devices for disease management and technology transfer from bench to bedside.
5 hour energy is a Farmington, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BIND Therapueitics is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.